Expansion and CD2/CD3/CD28 stimulation enhance Th2 cytokine secretion of human invariant NKT cells with retained anti-tumor cytotoxicity-Reference-Cited by-同舟云学术

Expansion and CD2/CD3/CD28 stimulation enhance Th2 cytokine secretion of human invariant NKT cells with retained anti-tumor cytotoxicity

Published:2020-05 Issue:5 Volume:22 Page:276-290
ISSN:1465-3249
Container-title:Cytotherapy
language:en
Short-container-title:Cytotherapy

Author:

Andrews Kelly,Hamers Anouk A.J.,Sun Xiaodian,Neale Geoffrey,Verbist Katherine,Tedrick Paige,Nichols Kim E.^ORCID,Pereira Shalini,Geraghty Daniel E.,Pillai Asha B.^ORCID

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Transplantation,Cell Biology,Genetics (clinical),Oncology,Immunology,Immunology and Allergy

Reference78 articles.

1. Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans;Metelitsa;Clinical immunology (Orlando, Fla.),2011

2. Natural killer T (NKT) cells and their role in antitumor immunity;Brutkiewicz;Critical reviews in oncology/hematology,2002

3. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas;Crowe;J Exp Med,2002

4. Combined natural killer T-cell based immunotherapy eradicates established tumors in mice;Teng;Cancer research,2007

5. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity;Wilson;Nat Rev Immunol,2003

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid Generation of Therapeutic Nanoparticles Using Cell‐Free Expression Systems;Small Methods;2023-04-28

2. Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy;Blood;2023-02-23

3. Characterization of the tumour microenvironment phenotypes in malignant tissues and pleural effusion from advanced osteoblastic osteosarcoma patients;Clinical and Translational Medicine;2022-10-28

4. Editorial: Innate immune cell therapy of cancer;Frontiers in Immunology;2022-08-19

5. iNKT: A new avenue for CAR-based cancer immunotherapy;Translational Oncology;2022-03